These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 37633973)
1. FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner. Kim JW; Kim MJ; Han TH; Lee JY; Kim S; Kim H; Oh KJ; Kim WK; Han BS; Bae KH; Ban HS; Bae SH; Lee SC; Lee H; Lee EW Cell Death Dis; 2023 Aug; 14(8):567. PubMed ID: 37633973 [TBL] [Abstract][Full Text] [Related]
2. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Koppula P; Lei G; Zhang Y; Yan Y; Mao C; Kondiparthi L; Shi J; Liu X; Horbath A; Das M; Li W; Poyurovsky MV; Olszewski K; Gan B Nat Commun; 2022 Apr; 13(1):2206. PubMed ID: 35459868 [TBL] [Abstract][Full Text] [Related]
3. Emmanuel N; Li H; Chen J; Zhang Y Oncotarget; 2022 Oct; 13():1136-1139. PubMed ID: 36264074 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin synergizes with PRLX93936 to induce ferroptosis in non-small cell lung cancer cells. Liang Z; Zhao W; Li X; Wang L; Meng L; Yu R Biochem Biophys Res Commun; 2021 Sep; 569():79-85. PubMed ID: 34237431 [TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143 [TBL] [Abstract][Full Text] [Related]
9. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub. Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670 [TBL] [Abstract][Full Text] [Related]
10. Targeting Nrf2 for ferroptosis-based therapy: Implications for overcoming ferroptosis evasion and therapy resistance in cancer. Lee J; Roh JL Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166788. PubMed ID: 37302427 [TBL] [Abstract][Full Text] [Related]
11. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Shin D; Kim EH; Lee J; Roh JL Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884 [TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257 [TBL] [Abstract][Full Text] [Related]
13. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma. Sánchez-Ortega M; Garrido A; Cirauqui C; Sanz-Gonzalez L; Hernández MC; González-García A; Obregon K; Ferrer I; Paz-Ares L; Carrera AC Redox Biol; 2024 Sep; 75():103305. PubMed ID: 39137583 [TBL] [Abstract][Full Text] [Related]
14. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821 [TBL] [Abstract][Full Text] [Related]
15. Autophagy Inhibition Plays a Protective Role in Ferroptosis Induced by Alcohol via the p62-Keap1-Nrf2 Pathway. Zhao Y; Lu J; Mao A; Zhang R; Guan S J Agric Food Chem; 2021 Aug; 69(33):9671-9683. PubMed ID: 34388345 [TBL] [Abstract][Full Text] [Related]
16. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738 [TBL] [Abstract][Full Text] [Related]
17. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347 [TBL] [Abstract][Full Text] [Related]
18. Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404 [TBL] [Abstract][Full Text] [Related]
19. Trabectedin induces ferroptosis via regulation of HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 axis in non-small cell lung cancer cells. Cai S; Ding Z; Liu X; Zeng J Chem Biol Interact; 2023 Jan; 369():110262. PubMed ID: 36396105 [TBL] [Abstract][Full Text] [Related]
20. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells. Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]